This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here

This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here

Choose ELIQUIS® for your patients with NVAF

ELIQUIS® (apixaban) – an oral, direct factor Xa inhibitor - is indicated for:

  • Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II)1

Robust, clinical evidence for ELIQUIS in patients with NVAF

ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.1

Footnotes:

  • * There is limited experience of treatment with ELIQUIS at the recommended dose for NVAF patients when used in combination with antiplatelet agents in patients with ACS and / or undergoing PCI after haemostasis is achieved. ELIQUIS should be used with caution when co-administered with aspirin and / or P2Y12 inhibitors because these medicinal products typically increase the bleeding risk.1
  • ACS = Acute Coronary Syndrome   DVT = Deep Vein Thrombosis   NVAF = Non-Valvular Atrial Fibrillation   NYHA = New York Heart Association   PE = Pulmonary Embolism   PCI = Percutaneous Coronary Intervention   TIA = Transient Ischaemic Attack   VKA = Vitamin K Antagonist

References:

  1. ELIQUIS® (apixaban) Summary of Product Characteristics. Available at www.medicines.ie.
  2. Granger CB et al. N Engl J Med 2011; 365: 981–992.
  3. Lopes RD et al. N Engl J Med 2019; 365: 883–891.
  4. Lip GH et al. Stroke. 2018; 49: 2933–2944.

Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at www.hpra.ie

Adverse reactions should also be reported to Bristol Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com